Curespec offers a medical device solution that uses noninvasive shockwave therapy for the treatment of hypertension and chronic kidney disease (CKD). The company’s technology is designed to generate new blood vessels and restore function to damaged tissue.

Curespec’s first market-ready product, Nephrospec, is a safe, low-intensity, noninvasive shockwave device delivering electro-hydraulic acoustic therapy (eHAT) intended for the interrelated treatment of hypertension and CKD. Designed to save up to 80% of costs while reducing suffering and needless loss of life, Nephrospec can improve kidney function in weeks, delay onset of dialysis with outpatient treatment, and function as a complementary solution to optimal medical care for hypertension and CKD.

Curespec has obtained CE and AMAR approval in Europe and Israel respectively.